| Literature DB >> 25565779 |
Ji-Wei Wang1, Zhi-Qi Yang1, Cong Liu1, Si-Jia Chen1, Qian Shen1, Tian-Rui Zhang1, Nancy S Partike2, Zheng-Ping Yuan3, Jin-Ming Yu1.
Abstract
BACKGROUND: In the People's Republic of China, both western medicine (WM) and traditional Chinese medicine (TCM) are the main treatment and rehabilitation options for cancer patients. This study aimed to explore cancer survivors' perspectives and experience of treatment and rehabilitation, in order to promote patient-centered activities of treatment and rehabilitation.Entities:
Keywords: adherence; cancer survivor education; focus group interview; preference
Year: 2014 PMID: 25565779 PMCID: PMC4274133 DOI: 10.2147/PPA.S76617
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Interview questions
| 1. What influence did the treatment and rehabilitation have upon your health and/or disease? |
| 2. What kind of treatment and rehabilitation did you feel that you needed? |
| 3. What kind of treatment and rehabilitation have you received? |
| 4. What did you think of the traditional Chinese medicine’s effects on your personal experiences with cancer treatment and rehabilitation? |
| 5. What did you think of the western medicine’s effects on your personal experiences with cancer treatment and rehabilitation? |
| 6. What is the most impressive thing you have experienced in the cancer treatment and rehabilitation? |
| 7. Do you have any further comments? |
Demographic characteristics of the cancer patients interviewed (n=68)
| Characteristics | n (%) |
|---|---|
| 42–49 | 4 (5.88) |
| 50–59 | 26 (38.24) |
| 60–69 | 31 (45.59) |
| 70–78 | 7 (10.29) |
| Male | 18 (26.47) |
| Female | 50 (73.53) |
| Junior high school or low | 25 (36.76) |
| Senior high school | 24 (35.29) |
| Junior college and tech college | 11 (16.18) |
| University | 8 (11.76) |
| Breast cancer | 31 (45.59) |
| Colorectal and rectal cancer | 10 (14.71) |
| Lung cancer | 7 (10.29) |
| Leukemia | 6 (8.82) |
| Lymphoma | 4 (5.88) |
| Thyroid cancer | 3 (4.41) |
| Liver cancer | 2 (2.94) |
| Ovarian cancer | 2 (2.94) |
| Tongue cancer | 1 (1.47) |
| Nasopharyngeal cancer | 1 (1.47) |
| Endometrial cancer | 1 (1.47) |
| <1 | 1 (1.47) |
| 1–2 | 4 (5.88) |
| 3–4 | 11 (16.18) |
| ≥ 5 | 52 (76.47) |
| Up to 2,000 | 15 (22.06) |
| 2,001–3,000 | 20 (29.41) |
| 3,001–4,000 | 139 (19.12) |
| 4,001–5,000 | 13 (19.12) |
| >5,000 | 7 (10.29) |